FDA Expands Clearance for Agendia's MammaPrint | GenomeWeb

NEW YORK (GenomeWeb News) – Agendia today said that the US Food and Drug Administration has cleared its MammaPrint breast cancer recurrence test for all ages.

Amsterdam-based Agendia said that it is the fourth FDA clearance for MammaPrint over the past three years. It also noted that MammaPrint has been approved in Europe for all ages since 2004.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.